TPIAO (Recombinant human thrombopoietin (rhTPO)) eShow Global
TPIAO (Recombinant human thrombopoietin (rhTPO))

沈阳三生制药有限责任公司

Shenyang Sunshine Pharmaceutical Co. Ltd.,

China    City:Shenyang

Contact information
Visible after login
Product Promotion Page
Comment
Product Details

In 2005, TPIAO was listed and has been approved by the CFDA for two indications that are the treatment of chemotherapy-induced thrombopenia (approved in 2005) and immune thrombocytopenia (ITP) (approved in 2010), which is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.

Comment
Comment